Affiliations: [a] University of Montpellier, Montpellier, France | [b] BioCommunication en CardioMétabolique (BC2M), University of Montpellier, Montpellier France | [c] Department of Neurology, Memory Research and Resources Center, Montpellier University Hospital, University of Montpellier, Montpellier, France | [d] Clinical Proteomics Platform, LBPC, IRMB, CHU Montpellier, Montpellier University, Montpellier, France
Correspondence:
[*]
Correspondence to: Dr. Audrey Gabelle, Memory Research and Resources Center, Department of Neurology, Gui de Chauliac Hospital, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5; University of Montpellier, Montpellier, France. Tel.: +33 467337363; E-mail: a-gabelle@chu-montpellier.fr.
Abstract: As of 2018, Alzheimer’s disease (AD) is the most common form of neurodegenerative dementia. It contributes to a progressive neuron loss, deterioration of memory, and cognitive impairment. Current therapies may provide a symptomatic benefit, but do not treat the underlying process. Ongoing researches focus on understanding the causal mechanisms and finding neuropathological hallmarks of AD. Therapeutic approaches targeting senile plaques or neurofibrillary tangles have not yet resulted in a significant cognitive improvement. However, recent data according to the analysis of AD clinical trials (clinicaltrials.gov database) show promising results. This literature review aims at summarizing the recent advances and at highlighting the most promising results of the ongoing researches. It compares the merits of small-molecules, antibodies, cell, and gene-based therapies and emphasizes the need for treatment at earlier stages of the disease.
Keywords: Alzheimer’s disease, amyloid-β peptides, amyloid-β protein precursor secretases, cell- and tissue-based therapy, early onset, genetic therapy, immunotherapy, tau proteins
